Wildfire smoke is causing air quality to plummet across Canada — 8 best AHAM-certified air purifiers for 2025
This year's wildfire season is shaping up to be Canada's second-worst on record, as wildfires continue to rage in Saskatchewan, Manitoba and Vancouver Island, B.C. The 2025 wildfire season has scorched "significantly more" area than the 10-year average, according to Natural Resources Canada and has played a significant role in deteriorating air quality across the country.
As of Tuesday morning, Toronto's air quality was among the 15 worst in the world, with surrounding American cities, including Detroit, New York City and Chicago, also topping the list.
On days with poor air quality, people are more likely to experience shortness of breath, difficulty breathing and coughing or wheezing — especially if they have a chronic respiratory disease like asthma or chronic obstructive pulmonary disease (COPD).
The small particles in wildfire smoke can get into your eyes and bloodstream, and if you have a heart or lung problem, you may experience problems earlier and at lower smoke levels.
According to Health Canada, using a portable air purifier that can filter fine particles is one way to protect your indoor environment from smoke pollution.
Air purifiers, also known as air cleaners, can improve indoor air quality by removing small contaminants that can harm your health.
According to the health authority, you should prioritize the following when choosing an air purifier:
Look for a device certified by the Association of Home Appliance Manufacturers (AHAM).
Choose an air purifier sized appropriately for the room you want to put it in.
Consider the clean air delivery rate (CADR) for the room size. The CADR describes how well the device reduces tobacco smoke, dust, pollen and wildfire smoke. To reduce fine particles, select a device with the highest CADR.
Choose an air purifier with a high-efficiency particulate air (HEPA) filter.
Avoid devices that produce ozone.
Best air purifiers for wildfire smoke
Not all air purifiers are made equal. Following Health Canada's recommendations, we've listed eight AHAM-certified air purifiers and included information about recommended room sizes and CADR ratings.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Low-income renters press governments for ways to cool apartments in heat waves
HALIFAX — Sandra Walsh was struggling to breathe in her apartment when temperatures across Nova Scotia soared in July, but the woman on social assistance says her pleas for a government-funded air conditioner have been ignored. "With the high humidity, it effects my breathing and I have to gasp for air," says the 46-year-old woman, recently diagnosed with a progressive lung disease. "Even taking frequent, cold showers isn't really helping." The resident of New Glasgow, N.S., is among many low-income Canadians with health conditions struggling to get government help to stay cool. She wants to buy a $300 air conditioner, but that would leave her with little money for food or medications. As of Wednesday, Walsh said it had been more than two months since she asked her income assistance caseworker for money to pay for an air conditioner. She said she has made the same request every summer since 2020, but has been refused. Similar struggles over what advocates call the "right to cooling" are gaining attention across the country. Renters' groups argue AC units are sometimes required to prevent illness and death, and some experts are calling for wider solutions that could include public cooling centres. Last year, another resident of New Glasgow, Julie Leggett, won an appeal before an adjudicator who decided the province had to pay for air conditioner due to her chronic pain condition. But the ruling only applies to Leggett. Nova Scotia's Department of Social Development said in a recent statement its policy of refusing to cover the cost of air conditioners for low-income people with health conditions has not changed. "In situations where health risks are worsened by extreme heat, caseworkers may refer individuals to local charities such as St. Vincent de Paul or churches," a spokeswoman for the department said in an email. Meanwhile, the province says Efficiency Nova Scotia — a non-profit energy conservation utility — can help landlords purchase heat pumps for affordable housing. Leggett says these solutions aren't always available to people living in poverty. "The province should not be trying to push its legal obligations onto non-profits that are already maxed out," she wrote in an email. In Ottawa, where temperatures soared in mid-July, 75-year-old apartment dweller Marie Lourdes Garnier said provincial governments should be helping low-income renters purchase air conditioners. She said her apartment was stifling during a recent heat wave, adding that in recent weeks she's found herself growing faint despite continually splashing cold water on her head. A spokesperson for the Ontario government said people on income assistance can apply for an air conditioner when municipal or First Nations programs permit it. In addition, people with disabilities can apply through the Ontario Disabilities Support Program. And the City of Toronto recently started offering a pilot program for low-income seniors. Garnier, who lives on a small pension, isn't eligible for these programs because she is not receiving income assistance. "It's very, very expensive for me ... (and) I'm not talking about (needing an AC unit) for comfort. It's a matter of life and death." Last year, an advocacy group for low-income renters known as ACORN found that a "negligible proportion" of its membership received public funds to buy an air conditioner or heat pump. A majority of the 737 people who responded to a survey reported poor sleep, fatigue and headaches from excessive indoor heat. In Moncton, N.B., Peter Jongeneelen — vice chair of ACORN New Brunswick — said that during a recent heat wave, he was admitted to an ER because he was suffering from heat exhaustion. He said people living on disability pensions need help, "(but) there's no real programs out there in New Brunswick. It's something we would like to change." Meanwhile, the number of people showing up at emergency rooms with heat-related problems continues to rise. Last month, Health Canada reported this type of case rose from about 600 in 2004 to about 1,100 in 2023. In British Columbia, where a "heat dome" in the summer of 2021 caused 600 deaths, the province committed $30 million in 2023 for a free air conditioner program run by BC Hydro. Since then, about 27,500 free AC units have been installed, the utility said. Still, University of British Columbia researcher Liv Yoon says the program has faced challenges. Some landlords, for example, have said their buildings simply can't support air conditioning. Yoon, co-author of a report titled "A Right to Cool," said there's a need for public cooling centres and access to free public transit to reach them. The report also calls for creation of affordable housing that includes passive shade systems to reduce indoor heat. Alex Boston, a B.C.-based urban planner and consultant, said air conditioners may be necessary for some low-income renters, but other solutions are often available. Indoor temperatures can be lowered by using window shades and fans, he said in an interview. Simple shading and air movement can decrease indoor temperatures by as much as 10 C, he said. In New Glasgow, Walsh said shades and fans might help. "But a refusal (of assistance) would mean I would suffer and not be able to breath with the extreme heat, which can lead to death," she said. This report by The Canadian Press was first published Aug. 6, 2025. Michael Tutton, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
3 hours ago
- CBS News
L.A. fires led to more than 400 additional deaths, study finds
The fires that ravaged Los Angeles at the beginning of this year took 31 lives by the official count, but new research estimates there were hundreds more deaths that are attributable to the disaster. In the study, published in the medical journal JAMA on Wednesday, researchers analyzed data on the number of deaths in Los Angeles County from Jan. 5 to Feb. 1, 2025 — the period when the Palisades and Eaton fires tore though the city — and estimated that 440 more deaths could be attributed to the fires, compared to the expected number based on data from previous years. These additional deaths likely reflect a combination of factors, including increased exposure to poor air quality, which may exacerbate heart or lung conditions, the authors say. They also point to the impact of delays or interruptions in people's access to necessary health care during that period. "The findings from this study underscore the need to complement direct fatalities estimates with alternative methods to quantify the additional mortality burden of wildfires and of climate-related emergencies more broadly," the authors wrote. "They also highlight the need for improved mortality surveillance during and after wildfire emergencies." The study did have some limitations, including some provisional data, and it did not account for deaths that may have occurred after Feb. 1. The authors suggest future research should look into the longer-term impacts of the wildfires as more data becomes available. They also urged more research into the causes contributing to excess deaths related to wildfires. The JAMA Network also published two studies Wednesday examining the health impacts of the Maui wildfires, which devastated the island in August 2023. In one study, researchers found substantial heart, lung and psychological health issues among a group of adults affected by the wildfires. Among the more than 1,000 study participants, nearly 63% had high blood pressure, nearly 50% reported depressive symptoms and about 22% exhibited FEV, or "forced expiratory volume," a measure of lung function. Additionally, researchers found that members of the study group who resided within the fire perimeter had "significantly lower lung function" compared with those outside it. A higher level of social support was associated with improved mental health outcomes, but researchers found it did not appear to improve physiological conditions like reduced lung function. "As climate-driven disasters intensify, proactive strategies to monitor and mitigate their long-term health effects will be essential to protect vulnerable populations and enhance resilience," the authors wrote. Another study focused on suicides and overdoses in the wake of the disaster. That research found that the fires did have an immediate effect on these types of deaths both in Maui and across Hawaii. Using data from the U.S. National Center for Health Statistics from January 2014 through December 2023, researchers found the fires were associated with a 46% increase in the suicide and overdose death rate in all of Hawaii in August 2023, relative to other months, and a 97% increase that month in Maui alone. During the 120-month study period, August 2023 accounted for both Maui's and other Hawaiian counties' highest monthly combined suicide and overdose death rate. The authors note these findings highlight the importance of "rapidly deploying suicide and overdose prevention interventions during wildfire response and recovery phases," including interventions that reach beyond directly-impacted areas.
Yahoo
5 hours ago
- Yahoo
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") and obesity industry update. The market for obesity and diabetes control drugs such as GLP-1 is growing at faster rates than nearly anyone originally anticipated, with revenues now expected to exceed $150 billion by 2030. Today these markets are overwhelmingly dominated by Eli Lilly and Company® and Novo Nordisk®, but with compelling growth opportunities abounding, no less than 39 new GLP-1 drugs are in development from 34 different companies. These tremendous growth opportunities in the GLP-1 sector have all of these companies racing to deliver improved products to the market. As reported earlier, perhaps the largest opportunity for product improvement is in the area of patient safety. The existing medications in the market today notoriously cause unwanted adverse events ("AEs"), more specifically gastrointestinal ("GI") AEs (nausea, vomiting, diarrhea, and constipation). To that end, Lexaria is working to position its DehydraTECH drug delivery technology as not only an improved drug absorption/performance enhancer, but also as a vital enabler of reducing side effects of various GLP-1 drugs. The following table summarizes the dramatic improvements in GI AEs that Lexaria has realized when testing all three (semaglutide, tirzepatide, and liraglutide) of the major GLP-1 drugs on the market today with its DehydraTECH ("DHT") technology in an oral format: Lexaria Study Control Test Article % Reductions vs Control GI AEs GLP-1-H24-1 GLP-1-H24-2* GLP-1-H24-3 GLP-1-H24-4** GLP-1-H24-4** GLP-1-H25-5 Rybelsus® (oral) Rybelsus® (oral) Zepbound® (injectable) Rybelsus® (oral) Rybelsus® (oral) Saxenda® (injectable) DHT-Rybelsus® (oral) DHT-Rybelsus® (oral) DHT-tirzepatide (oral) DHT-semaglutide (oral) DHT-tirzepatide (oral) DHT-liraglutide (oral) -60% -100% -57% -43% -57% -31% * oral dosing was performed after overnight fasting in all instances, except for GLP-1-H24-2 where fed pre-dosing conditions were applied.** partial/8-week results from 12-week study Meanwhile, pharmaceutical companies large and small are jockeying for position in what has effectively become a technological arms race. On May 14th Novo Nordisk® announced that it had struck a collaboration and licensing deal with Septerna™ to develop molecules of use in the obesity and type 2 diabetes sectors, in return for up front and milestone payments of up to $2.2 billion. On March 12th Roche® announced it had acquired rights to obesity drug petrelintide from Zealand Pharma A/S® for up to $5.3 billion in payments. The Roche transaction allows them to potentially gain more rapid access to the market sector than may have been possible from its own obesity drug, CT-388 which is still undergoing development and assessment. Regeneron® launched itself into the GLP-1 arms race with its licensing and milestone deal announced June 2nd, worth up to $1.93 billion to acquire rights to China's Hansoh Pharmaceutical Group's™ HS-20094 which is a dual GLP-1/GIP receptor agonist. On April 15th, Merck® announced a licensing deal worth up to $493 million for limited rights to Cyprumed's™ oral peptide drug delivery technology. What is particularly notable is that these rights are non-exclusive, with additional payments required if Merck® was to exercise their option for exclusive rights. With an extensive wholly-owned patent portfolio protecting DehydraTECH worldwide, Lexaria continues to take steps to unlock the value of its robust drug delivery platform. As the diabetes control and weight-loss industries continue to focus on GLP-1 and even more advanced drug generations for these and other therapeutic indications, Lexaria remains confident that DehydraTECH is valid for utilization with the right commercial partner(s). About Lexaria Bioscience Corp. & DehydraTECH DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide. For more information, please visit CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. INVESTOR CONTACT: George Jurcic - Head of Investor Relationsir@ 250-765-6424, ext 202 SOURCE: Lexaria Bioscience Corp. View the original press release on ACCESS Newswire Sign in to access your portfolio
